All In Biotech

Drug Trial Radar · NCT06200597

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

A Phase 1 Randomized, 2-part, Single-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of LAD603 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

92

Actual

Start

Dec 5, 2023

Primary completion

May 11, 2025

Study completion May 29, 2025

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
Jan 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple ascending doses of LAD603 in healthy adult participants in both Part 1 and 2.

Conditions

  • Healthy Volunteers

Interventions

  • LAD603Drug

    LAD603 SC injection.

  • PlaceboOther

    Matching placebo SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Adverse Events (AEs) and Severity of AEsTime frame: Baseline up to Day 31
  2. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign ParameterTime frame: Baseline up to Day 31
  3. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Electrocardiograms (ECGs) ParametersTime frame: Baseline up to Day 31
  4. Part 1: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory ParametersTime frame: Baseline up to Day 31
  5. Part 2: Number of Participants with AEs and Severity of AEsTime frame: Baseline up to Day 64
  6. Part 2: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign ParameterTime frame: Baseline up to Day 64
  7. Part 2: Number of Participants with Clinically Significant Changes from Baseline in ECGs ParametersTime frame: Baseline up to Day 64
  8. Part 2: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory ParametersTime frame: Baseline up to Day 64

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Phase 1 unit Lenexa

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.